• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.

作者信息

Bishop David C, Clancy Leighton E, Simms Renee, Burgess Jane, Mathew Geetha, Moezzi Leili, Street Janine A, Sutrave Gaurav, Atkins Elissa, McGuire Helen M, Gloss Brian S, Lee Koon, Jiang Wei, Maddock Karen, McCaughan Georgia, Avdic Selmir, Antonenas Vicki, O'Brien Tracey A, Shaw Peter J, Irving David O, Gottlieb David J, Blyth Emily, Micklethwaite Kenneth P

机构信息

Westmead Institute for Medical Research, Sydney, NSW, Australia.

Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

出版信息

Blood. 2021 Oct 21;138(16):1504-1509. doi: 10.1182/blood.2021010813.

DOI:10.1182/blood.2021010813
PMID:34010392
Abstract
摘要

相似文献

1
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.在10例接受piggyBac修饰的CD19嵌合抗原受体（CAR）T细胞有效治疗的患者中，有2例发生了CAR T细胞淋巴瘤。
Blood. 2021 Oct 21;138(16):1504-1509. doi: 10.1182/blood.2021010813.
2
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.猪源 Bac 修饰的 CD19 嵌合抗原受体 T 细胞输注后产品相关淋巴瘤的研究。
Blood. 2021 Oct 21;138(16):1391-1405. doi: 10.1182/blood.2021010858.
3
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.用表达抗 CD19 嵌合抗原受体的 T 细胞治疗 B 细胞癌。
Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2.
4
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.B细胞非霍奇金淋巴瘤患者自体造血干细胞移植后中枢记忆来源的CD19嵌合抗原受体T细胞疗法的1期研究。
Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26.
5
Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.生成靶向 CD19 的嵌合抗原受体 T 细胞。
Arch Iran Med. 2019 Jan 1;22(1):7-10.
6
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.双特异性抗 CD20、抗 CD19 CAR T 细胞治疗复发 B 细胞恶性肿瘤：1 期剂量递增和扩展试验。
Nat Med. 2020 Oct;26(10):1569-1575. doi: 10.1038/s41591-020-1081-3. Epub 2020 Oct 5.
7
Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.嵌合抗原受体修饰 T 细胞疗法治疗 B 细胞非霍奇金淋巴瘤。
Am J Hematol. 2019 May;94(S1):S18-S23. doi: 10.1002/ajh.25403. Epub 2019 Jan 24.
8
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.选择最佳 CAR-T 细胞疗法治疗 B 细胞恶性肿瘤。
Curr Hematol Malig Rep. 2021 Feb;16(1):32-39. doi: 10.1007/s11899-021-00615-7. Epub 2021 Feb 25.
9
Determination of Cytotoxic Potential of CAR-T Cells in Co-cultivation Assays.在共培养实验中测定CAR-T细胞的细胞毒性潜力。
Methods Mol Biol. 2020;2086:213-222. doi: 10.1007/978-1-0716-0146-4_16.
10
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.建设 CAR 车库：纪念斯隆凯特琳癌症中心准备接收商业 CAR T 细胞产品。
Biol Blood Marrow Transplant. 2018 Jun;24(6):1135-1141. doi: 10.1016/j.bbmt.2018.02.018. Epub 2018 Mar 1.

引用本文的文献

1
Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.与治疗干预相关的非典型淋巴样增殖：2024年EA4HP/SH淋巴瘤研讨会报告
Virchows Arch. 2025 Aug 13. doi: 10.1007/s00428-025-04197-0.
2
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy.在CAR-T治疗后被诊断为T细胞淋巴瘤的克隆性扩增的淋巴结T细胞群体。
Nat Commun. 2025 Aug 12;16(1):7462. doi: 10.1038/s41467-025-62709-7.
3
The derived transposase 5 (PGBD5) can interact with human -like elements.
衍生转座酶5（PGBD5）可与人源样元件相互作用。
bioRxiv. 2025 Aug 2:2025.07.31.667870. doi: 10.1101/2025.07.31.667870.
4
Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system.通过表达针对WT1的转基因T细胞受体、针对GM-CSF受体的嵌合抗原受体、针对CD33的双特异性T细胞衔接器以及tEGFR自杀基因系统的五基因工程化T细胞靶向急性髓系白血病。
Immunother Adv. 2025 Jun 11;5(1):ltaf022. doi: 10.1093/immadv/ltaf022. eCollection 2025.
5
Unveiling Genomic Rearrangements in Engineered iPSC Lines by Optical Genome Mapping.通过光学基因组图谱揭示工程化诱导多能干细胞系中的基因组重排
bioRxiv. 2025 May 11:2025.05.10.653237. doi: 10.1101/2025.05.10.653237.
6
Safety and Efficacy of CD19-Targeted Chimeric Antigen Receptor (CAR) T-cells Generated Using DNA Transposon Systems: A Meta-Analysis.使用DNA转座子系统生成的CD19靶向嵌合抗原受体（CAR）T细胞的安全性和有效性：一项荟萃分析。
Cureus. 2025 Apr 8;17(4):e81930. doi: 10.7759/cureus.81930. eCollection 2025 Apr.
7
Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.通过非病毒工程和高度多重碱基编辑提高CAR-NK细胞的精准度。
J Immunother Cancer. 2025 May 7;13(5):e009560. doi: 10.1136/jitc-2024-009560.
8
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?长期B细胞淋巴瘤缓解者接受靶向CD19的嵌合抗原受体T细胞疗法后的髓系肿瘤，风险会随时间增加吗？
Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02605-7.
9
CAR-NK cell therapy: promise and challenges in solid tumors.嵌合抗原受体自然杀伤细胞（CAR-NK）疗法：实体瘤治疗中的前景与挑战
Front Immunol. 2025 Apr 7;16:1574742. doi: 10.3389/fimmu.2025.1574742. eCollection 2025.
10
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges.胃肠道癌症中的嵌合抗原受体T细胞疗法：当前临床试验及克服挑战的策略
Nat Rev Gastroenterol Hepatol. 2025 Apr 14. doi: 10.1038/s41575-025-01062-y.